Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Penimepicycline** is an older systemic antibacterial agent and the phenoxymethylpenicillinate salt of pipacycline, a tetracycline also known as mepicycline. The pipacycline moiety inhibits bacterial protein synthesis through the 30S ribosomal subunit, while the phenoxymethylpenicillin moiety contributes beta-lactam antibacterial activity through inhibition of penicillin-binding proteins involved in peptidoglycan cell-wall synthesis. It was historically administered orally or intramuscularly and studied or used for bacterial infections including urological, respiratory, gynecological, and other infections. Historical reports describe bactericidal activity against streptococci and bacteriostatic activity against a range of gram-positive and gram-negative bacteria.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on penimepicycline.